within Pharmacolibrary.Drugs.ATC.B;

model B01AD11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 119 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.0062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tenecteplase is a genetically engineered variant of tissue plasminogen activator (tPA) used as a thrombolytic agent. It is indicated primarily for the treatment of acute myocardial infarction (ST-segment elevation myocardial infarction, STEMI) to dissolve blood clots in coronary arteries. It is approved in many countries and used in hospital emergency settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with acute myocardial infarction after a single intravenous bolus injection.</p><h4>References</h4><ol><li><p>Wang, L, et al., &amp; Xiong, Y (2024). Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> 13(9) e031692–None. DOI:<a href=&quot;https://doi.org/10.1161/JAHA.123.031692&quot;>10.1161/JAHA.123.031692</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38686848/&quot;>https://pubmed.ncbi.nlm.nih.gov/38686848</a></p></li><li><p>Dittmar, E, et al., &amp; De Los Rios La Rosa, F (2023). Conversion From Intravenous Alteplase to Tenecteplase for Treatment of Acute Ischemic Stroke Across a Large Community Hospital Health System. <i>The Annals of pharmacotherapy</i> 57(10) 1147–1153. DOI:<a href=&quot;https://doi.org/10.1177/10600280221149409&quot;>10.1177/10600280221149409</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36688289/&quot;>https://pubmed.ncbi.nlm.nih.gov/36688289</a></p></li><li><p>Tanswell, P, et al., &amp; Danays, T (2002). Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. <i>Clinical pharmacokinetics</i> 41(15) 1229–1245. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200241150-00001&quot;>10.2165/00003088-200241150-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12452736/&quot;>https://pubmed.ncbi.nlm.nih.gov/12452736</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AD11;
